Sign or Symptom – Talk Bio

Ambros Therapeutics launches with $125M to develop non-opioid chronic pain drug neridronate

4 weeks ago talkbio0Tagged * * Vivek Ramaswamy * *, 6-amino-1-hydroxyhexane-1,1-diphosphonate, Ambros Therapeutics, Analgesics, Non-Narcotic, Chronic pain, Complex Regional Pain Syndromes, CRPS-1, Diphosphonates, Series A

Ambros Therapeutics; $125 million Series A; chronic pain; complex regional pain syndrome type 1; CRPS-1; neridronate; non-opioid analgesic; bisphosphonate; Vivek Ramaswamy; biotech financing

Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data

1 month ago talkbio0Tagged American Epilepsy Society 2025, Antisense Oligonucleotides, Biogen, blockbuster drug, EMPEROR Phase III trial, Epilepsy, Infantile Severe Myoclonic Epilepsy, Jefferies analysts, natural history controls, SCN1A gene, Seizures, Stoke Therapeutics, Zorevunersen

Biogen; Stoke Therapeutics; zorevunersen; Dravet syndrome; epilepsy; antisense oligonucleotide; seizure reduction; blockbuster drug; EMPEROR Phase III trial; American Epilepsy Society 2025; Jefferies analysts; natural history controls; SCN1A

FDA Moves to Remove Black Box Warnings from Menopausal Hormone Therapies

2 months ago talkbio0Tagged Black Box Warning, estrogens, Hormone replacement therapy, Hormone Therapy, labeling change, Menopausal symptom, Menopause, Progestins, United States Food and Drug Administration, women 's health

FDA; menopause; hormone therapy; black box warning; HRT; estrogen; progestogen; labeling change; women’s health; menopausal symptoms

Expert Flags Potential ‘Honeymoon Effect’ as Rapport Heads Towards Phase III Epilepsy Trials

2 months ago talkbio0Tagged Biological Markers, drug-resistant focal seizures, Epilepsy, Honeymoon Effect, KOL Bulletin, mid-stage, Phase 3 Clinical Trials, RAP-219, Rapport Therapeutics, Seizures

KOL Bulletin; honeymoon effect; Rapport Therapeutics; RAP-219; Phase III trials; epilepsy; drug-resistant focal seizures; seizure reduction; mid-stage data; biomarker

Bayer Receives FDA Approval for Lynkuet, a Novel Non-Hormonal Drug for Menopausal Hot Flashes

3 months ago talkbio0Tagged Approved, Bayer, Elinzanetant, Hot flushes, Lynkuet, Menopause, NK1/NK3 receptors, Non-Hormonal, United States Food and Drug Administration, vasomotor symptom

Bayer; FDA approval; Lynkuet; elinzanetant; hot flashes; menopause; non-hormonal; NK1/NK3 receptors; vasomotor symptoms

FDA Approves Bayer’s Lynkuet for Menopausal Hot Flashes

3 months ago talkbio0Tagged Approved, Bayer, Hot flushes, Lynkuet, Menopause, United States Food and Drug Administration

FDA approval; Bayer; Lynkuet; menopause; hot flashes

Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

4 months ago talkbio0Tagged anti-seizure medication, Clinical Development, drug-resistant epilepsy, Epilepsy, focal onset seizures, RAP-219, Rapport Therapeutics, Seizures

Rapport Therapeutics; RAP-219; epilepsy; seizure reduction; Phase 2a clinical trial; focal onset seizures; Phase 3 trials; anti-seizure medication; drug-resistant epilepsy; clinical development

Fierce Biotech Fundraising Tracker ’25: CHARM attracts $80M; Wugen reels in $115M

4 months ago talkbio0Tagged AI drug design, charmed, Drug Development, Leukemia, Myelocytic, Acute, Menin Inhibitor, NVIDIA, Series B funding, venture capital, Wugen

CHARM Therapeutics; AI drug design; menin inhibitor; acute myeloid leukemia (AML); Series B funding; venture capital; biotech fundraising; Wugen; NVIDIA; drug development

FDA Approves Tonix’s Tonmya: First New Fibromyalgia Drug in Over 15 Years

5 months ago talkbio0Tagged Analgesics, Non-Narcotic, Approved, Chronic pain, Clinical Trials, cyclobenzaprine, Fibromyalgia, Hairy Cell Leukemia, Phase 3, sublingual tablets, Tonix, Tonmya, United States Food and Drug Administration

Tonmya; FDA approval; fibromyalgia; Tonix Pharmaceuticals; non-opioid analgesic; cyclobenzaprine HCl sublingual tablets; chronic pain; phase 3 clinical trials

Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion

5 months ago talkbio0Tagged Acute onset pain, Approved, Drug Development, Journavx, non-opioid pain drugs, Pain management, Peripheral neuropathic pain, Sodium Channel Blockers, United States Food and Drug Administration, VX-993

Vertex Pharmaceuticals; Journavx; VX-993; pain management; acute pain; phase 2 clinical trial; sodium channel inhibitor; non-opioid pain drugs; FDA approval; peripheral neuropathic pain; drug development